EGFR and lung carcinoma: Unlike other oncogenic changes that have already become attractive drug targets, such as EGFR mutations and ALK, ROS and RET rearrangements, K-ras mutations are still viewed as “undruggable.” However, studies have shown that K-ras mutant lung cancer is strongly associated with inflammation which renders a new target for tackling this disease.